Why Baxter International Inc.’s (BAX) Stock Is Up 5.75%
As of Monday, August 03, Baxter International Inc.’s BAX share price has surged by 5.75%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: Baxter International Inc. (BAX)
Baxter International Inc. BAX
$26.27
-0.15
-0.55%
August 21, 2026 2:31:04 PM
EST
Volume: 1,649,117
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NYSE | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Commentary & Analysis
Why Baxter International Inc.’s (BAX) Stock Is Up 16.01%
As of Thursday, July 30, Baxter International Inc.’s BAX share price has surged by 16.01%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
What You Need to Know About Baxter International Inc.'s Q3 Earnings
Baxter International Inc.'s fiscal Q3 earnings report was released on Thursday, July 30. Let's dive in to see if (BAX) missed or beat analyst's expectations.Michael Rose
Is Baxter International Inc. (BAX) Overvalued?
We dive into why Baxter International Inc. (BAX) could be considered overvalued on 2026-07-23, based on AAII’s Value Score and Grade.Jenna Brashear
Which Is a Better Investment, Baxter International Inc. or NovoCure Limited Stock?
Learn more about whether Baxter International Inc. or NovoCure Limited is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Financial Summary
| Share Statistics | BAX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $13,653.9 | $407.7 | 81% |
|
| Shares Out (Mil) | 518.0 | 41.3 | 89% |
|
| Institutional Ownership | 99.6% | 81.4% | 91% |
|
| Float (Mil) | 514.5 | 34.9 | 85% |
|
| Beta | 0.60 | 0.88 | 35% |
|
| Avg Daily Volume (000s) | 6,371 | 412 | 94% |
|
| Price Change (52-week) |
8.6% | 64.8% | 52% |
|
| Growth | BAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (0.7%) | 11.8% | 15% |
|
| Net Income (5yr) | (23.5%) | (6.0%) | 17% |
|
| EPS (5yr) | (23.5%) | 10.4% | 11 |
|
| Dividends (5yr) | (11.4%) | 0.0% | 60% |
|
| Cash Flow (5yr) | (25.4%) | (16.2%) | 25% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 13 | 13 | |
| Current EPS | $0.519 | $2.047 | $2.036 | |
| Month Ago EPS | $0.533 | $1.918 | $2.005 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.532 | $1.917 | $2.011 | |
| Year/Year Chg | 99.6% | (216.7%) | (224.5%) | |
| Financials | BAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $11,470 | $119 | 85% |
|
| Net Income (TTM) (Mil) | ($1,063) | ($9) | 1% |
|
| EPS (TTM) | ($2.064) | ($0.400) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | $1,319 | ($3) | 84% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $8,823 | $21 | 90% |
|
| Enterprise Value (Q1) (Mil) | $21,454 | $427 | 84% |
|
| Valuation | BAX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.20 | 3.06 | 54% |
|
| P/E | na | 27.8 | na |
|
| Dividend Yield | 0.2% | 0.0% | 60% |
|
| PEG (5yr hist) | na | 1.7 | na |
|
| Ratios | BAX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 34.1% | 58.9% | 41% |
|
| Net Margin | (9.3%) | (6.9%) | 21% |
|
| ROA | (5.2%) | (12.7%) | 30% |
|
| ROE | (15.7%) | (13.1%) | 25% |
|
| Liabilities to Assets | 68.8% | 46.0% | 64% |
|
| F-Score | 3 | 4 | 18% |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Kirkpatrick Bargain Screen
Factors: Value, Momentum
Investing model outlined in Charles Kirkpatrick's book, Beat the Market: Invest by Knowing What Stocks to Buy and What Stocks to Sell.
| Performance Since Inception: | 6.8% |
| +/- S&P 500: | -0.7 |
